EsPhALL 2004 An Open-label, Randomized Phase II/III Study to Compare the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL) - EsPhALL 2004
Latest Information Update: 28 May 2019
At a glance
- Drugs Imatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms EsPhALL 2004
- 15 Sep 2016 New trial record